A kind of Mosapride citrate nanocrystalline chip and preparation method thereof
The preparation of mosapriligy citrate nanocrystals by high-pressure homogenization method and mixed with other dosage forms to press tablets, solving the problem of slow dissolution of insoluble drugs and achieving efficient dissolution and bioavailability of mosapriligy citrate Improved, suitable for industrial production.
Patent Information
- Application Number
- CN202210046356.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-01-13
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2042-01-13
AI Technical Summary
Insoluble drugs such as mosapriligy citrate are slow to dissolve in the dissolution medium, resulting in low bioavailability, and it is difficult for the prior art to effectively improve its solubility and dissolution rate.
The high-pressure homogenization method is used to prepare mosapriligy citrate nanocrystals and mix it with fillers, disintegrants, glidants, and lubricants to form mosapriligy citrate nanocitrate to improve its Dissolution rate.
It significantly improves the dissolution speed and bioavailability of mosapride citrate, simplifies the preparation process, reduces production costs, is suitable for large-scale production, and has good reproducibility.
Smart Images

Figure BDA0003469345860000021 
Figure BDA0003469345860000022 
Figure BDA0003469345860000051
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of pharmaceutical preparations, and in particular relates to a mosapride citrate nanocrystalline chip and a preparation method thereof. Background Art
[0002] Disintegration of solid preparations and dissolution of drug particles are key links in determining the oral absorption of solid preparations. According to statistics, 40% of the drugs marketed worldwide are poorly soluble drugs, and the proportion of poorly soluble candidate drugs in the research and development stage is as high as 90%. Poor solubility and low dissolution rate are the key reasons for the low bioavailability of many poorly soluble drugs. Increasing the solubility and dissolution rate of poorly soluble drugs and thus improving their oral bioavailability has become one of the most important research directions in the field of pharmacy.
[0003] The dissolution rate of a drug can be described by the Noyes-Whitney equation, i.e., dC / dt=KS(CS-C). According to this equation, the dissolution rate of a drug is proportional to the dissolution surface area, and reducing the particle size is the most effective measure to increase the dissolution rate. In recent years, nanocrystallization technology has been developed to improve the dissolution rate of poorly soluble drugs. When the diameter of drug particles is in the nanometer range, their intrinsic solubility will be greatly improved. Currently, the preparations developed and successfully marketed using this technology include megestrol acetate, fenofibrate, aprepitant, dexmethylphenidate hydrochloride, etc. The commonly used preparation methods of nanocrystals mainly include precipitation method, grinding method, high-pressure homogenization method, emulsified solvent evaporation method, and emulsified solvent diffusion method.
[0004] Mosapride citrate is mainly used to relieve digestive system symptoms associated with chronic gastritis, such as heartburn, early satiety, upper abdominal distension, upper abdominal pain, nausea, and vomiting. It can also be used for gastroesophageal reflux disease, diabetic gastroparesis, and gastric dysfunction in patients with partial gastrectomy. In the Japanese Orange Book dissolution database, the solubility of mosapride citrate raw material in various dissolution media is: pH 1.2: 0.152 mg / ml; pH 4.0: 0.246 mg / ml; pH 6.8: 0.002 mg / ml; water: 1.62 mg / ml, which belongs to Class II drugs in the Biopharmaceutics Classification System (BCS).
[0005] CN101273973B discloses a dispersible tablet containing mosapride citrate and a preparation method thereof. Although the tablet prepared by the patented technology can disintegrate quickly, mosapride citrate is a poorly soluble drug and may not be able to dissolve quickly in a dissolution medium after rapid disintegration. In order to increase the dissolution rate of mosapride citrate, the present invention uses a high-pressure homogenization method to prepare mosapride citrate nanocrystals, and the mosapride citrate nanocrystals, a filler, a disintegrant, a glidant, and a lubricant are mixed and compressed to obtain mosapride citrate nanocrystals, so as to improve the bioavailability of mosapride citrate. Summary of the invention
[0006] In view of the problems existing in the prior art, the purpose of the present invention is to provide a mosapride citrate nanocrystalline chip and a preparation method thereof. The mosapride citrate nanocrystalline chip is composed of mosapride citrate nanocrystalline, a filler, a disintegrant, a glidant, and a lubricant mixed tablet, and the mosapride citrate nanocrystalline is prepared by a high-pressure homogenization method from mosapride citrate and a stabilizer. The mosapride citrate nanocrystalline chip prepared by the present invention has a greatly improved dissolution rate, high bioavailability, fewer required processes, time-saving and energy-saving, small batch-to-batch differences, and is suitable for scaled-up production.
[0007] On the one hand, the present invention provides a mosapride citrate nanocrystalline chip, and the specific technical scheme is as follows:
[0008] A mosapride citrate nanocrystalline chip is composed of mosapride citrate nanocrystalline, a filler, a disintegrant, a glidant, and a lubricant, wherein the filler is one or more of microcrystalline cellulose, pregelatinized starch, mannitol, and lactose; the disintegrant is one or more of cross-linked polyvinylpyrrolidone, low-substituted hydroxypropyl cellulose, cross-linked sodium carboxymethyl cellulose, and sodium starch glycolate; the glidant is one or more of talc and silicon dioxide; and the lubricant is one or more of magnesium stearate and sodium stearyl fumarate.
[0009] Further preferably, the present invention obtains mosapride citrate nanocrystalline sheets by adding a filler, a disintegrant, a glidant, and a lubricant to the mosapride citrate nanocrystalline, mixing the mixture evenly, and then tableting the mixture.
[0010] Further preferably, the mosapride citrate nanocrystalline wafer formulation of the present invention is composed of the following compositions by mass percentage:
[0011] as follows:
[0012]
[0013] Preferably, the mass percentage composition is as follows:
[0014]
[0015]
[0016] Further preferably, the mosapride citrate nanocrystals are prepared from mosapride citrate and a stabilizer by a high-pressure homogenization method, and the specific preparation method comprises the following steps: preparing a stabilizer ethanol solution, dispersing mosapride citrate in the stabilizer ethanol solution to form a mosapride citrate suspension; placing the mosapride citrate suspension in a high-pressure homogenizer for high-pressure homogenization circulation to obtain mosapride citrate nanocrystals;
[0017] Mosapride mixture;
[0018] The mixed liquid is spray-dried to obtain mosapride citrate nanocrystals; a filler, a disintegrant, a glidant and a lubricant are added to the mosapride citrate nanocrystals, mixed evenly and then tableted to obtain mosapride citrate nanocrystalline sheets.
[0019] Further preferably, the stabilizer in step (1) is one or more of polyvinyl pyrrolidone, Tween 80, povidone K30, hydroxypropyl methylcellulose E5, and carbomer.
[0020] Further preferably, in the step (1), the mass ratio of the stabilizer to mosapride citrate is 1:(0.5-2).
[0021] Further preferably, the concentration of mosapride citrate in the mosapride citrate suspension is 10 mg / mL to 30 mg / mL.
[0022] Further preferably, the high-pressure homogenization circulation pressure in step (2) is 600 to 1000 bar, and the number of cycles is 5 to 20 times.
[0023] More preferably, the spray drying temperature in step (3) is 60-70°C.
[0024] Compared with the prior art, the present invention has the following beneficial effects:
[0025] The mosapride citrate nanocrystalline chip prepared by the invention has rapid dissolution and high bioavailability; meanwhile, the preparation process is simple, time-saving and energy-saving, and the result reproducibility is good, which is conducive to industrialized large-scale production. DETAILED DESCRIPTION
[0026] 1. Preparation of Mosapride Citrate Nanocrystals
[0027] Example 1
[0028] Preparation process: Measure 100mL of purified water, weigh 6g of povidone K30, add povidone K30 to purified water, stir to dissolve completely, and obtain a stabilizer solution. Weigh 6g of mosapride citrate raw material, add it to the above solution, ultrasonicate for 5 minutes to evenly disperse the raw material, and obtain a mosapride citrate suspension with a concentration of 60mg / mL. Then put it into a high-pressure homogenizer and circulate it 10 times at 1000bar to obtain a mosapride citrate nanocrystalline suspension. The particle size of the nanocrystalline suspension is measured using a Malvern particle size analyzer, D 50 The average value is 288nm, D 90 The average value is 731 nm. The prepared mosapride citrate nanocrystal suspension was dried in a spray dryer at a drying temperature of 70° C. to obtain mosapride citrate nanocrystal powder, and its solubility was measured.
[0029] Example 2
[0030] Preparation process: Measure 100mL of purified water, weigh 3g of povidone K30, add povidone K30 to the purified water, stir to dissolve completely, and obtain a stabilizer solution. Weigh 6g of raw materials, add them to the above solution, and ultrasonicate for 5 minutes to evenly disperse the raw materials to obtain a mosapride citrate suspension with a concentration of 60mg / mL. Then put it into a high-pressure homogenizer and circulate it 10 times at 1000bar to obtain a mosapride citrate nanocrystalline suspension. The particle size of the nanocrystalline suspension is measured using a Malvern particle size analyzer, D 50 The average value is 359nm, D 90 The average value is 863 nm. The prepared mosapride citrate nanocrystal suspension was dried in a spray dryer at a drying temperature of 70° C. to obtain mosapride citrate nanocrystal powder, and its solubility was measured.
[0031] Example 3
[0032] Preparation process: Measure 100mL of purified water, weigh 6g of Hydroxypropyl Methylcellulose E5, add Hydroxypropyl Methylcellulose E5 into purified water, stir to dissolve completely, and obtain a stabilizer solution. Weigh 6g of raw materials, add them to the above solution, and ultrasonicate for 5 minutes to evenly disperse the raw materials to obtain a mosapride citrate suspension with a concentration of 60mg / mL. Then put it into a high-pressure homogenizer and circulate it 10 times at 1000bar to obtain a mosapride citrate nanocrystalline suspension. The particle size of the nanocrystalline suspension is measured using a Malvern particle size analyzer, D 50 The average value is 225nm, D 90 The average value is 641 nm. The prepared mosapride citrate nanocrystal suspension was dried in a spray dryer at a drying temperature of 70° C. to obtain mosapride citrate nanocrystal powder, and its solubility was measured.
[0033] Example 4
[0034] Preparation process: Measure 100mL of purified water, weigh 3g of Hydroxypropyl Methylcellulose E5, add Hydroxypropyl Methylcellulose E5 into purified water, stir to dissolve completely, and obtain a stabilizer solution. Weigh 6g of raw materials, add them to the above solution, and ultrasonicate for 5 minutes to evenly disperse the raw materials to obtain a mosapride citrate suspension with a concentration of 60mg / mL. Then put it into a high-pressure homogenizer and circulate it 10 times at 1000bar to obtain a mosapride citrate nanocrystalline suspension. The particle size of the nanocrystalline suspension is measured using a Malvern particle size analyzer, D 50 The average value is 318nm, D 90 The average value is 731 nm. The prepared mosapride citrate nanocrystal suspension was dried in a spray dryer at a drying temperature of 70° C. to obtain mosapride citrate nanocrystal powder, and its solubility was measured.
[0035] 2. Preparation of Mosapride Citrate Nanochips
[0036] Example 5
[0037] Prescription (1000 tablets)
[0038]
[0039] Preparation process: Mosapride citrate nanocrystals were prepared by the preparation method of Example 3. The prescribed amount of mosapride citrate nanocrystals, lactose, pregelatinized starch, cross-linked carboxymethyl cellulose sodium, and silicon dioxide were weighed and mixed evenly, and magnesium stearate was added evenly. A shallow concave punching tablet with a diameter of 6.5 mm was selected, and the pressing speed and pressure were adjusted to obtain a tablet. The cumulative dissolution amount of the mosapride citrate nanocrystal was detected.
[0040] Example 6
[0041] Prescription (1000 tablets)
[0042]
[0043] Preparation process: Mosapride citrate nanocrystals were prepared by the preparation method of Example 3. The prescribed amount of mosapride citrate nanocrystals, lactose, microcrystalline cellulose, low-substituted hydroxypropyl cellulose, and silicon dioxide were weighed and mixed evenly, and magnesium stearate was added evenly. A shallow concave punching tablet with a diameter of 6.5 mm was selected, and the tableting speed and pressure were adjusted to obtain a tablet. The cumulative dissolution amount of the mosapride citrate nanocrystal was detected.
[0044] Example 7
[0045] Prescription (1000 tablets)
[0046]
[0047]
[0048] Preparation process: Mosapride citrate nanocrystals were prepared by the preparation method of Example 3. The prescribed amount of mosapride citrate nanocrystals, microcrystalline cellulose, mannitol, sodium carboxymethyl starch, and silicon dioxide were weighed and mixed evenly, and magnesium stearate was added evenly. A shallow concave punching tablet with a diameter of 6.5 mm was selected, and the tableting speed and pressure were adjusted to obtain a tablet. The cumulative dissolution amount of the mosapride citrate nanocrystal was detected.
[0049] Example 8
[0050] Prescription (1000 tablets)
[0051]
[0052] Preparation process: Mosapride citrate nanocrystals were prepared by the preparation method of Example 3. The prescribed amount of mosapride citrate nanocrystals, lactose, pregelatinized starch, cross-linked carboxymethyl cellulose sodium, and silicon dioxide were weighed and mixed evenly, and magnesium stearate was added evenly. A shallow concave punching tablet with a diameter of 6.5 mm was selected, and the tableting speed and pressure were adjusted to obtain a tablet. The cumulative dissolution amount of the mosapride citrate nanocrystal was detected.
[0053] Comparative Example 1
[0054] Prescription (1000 tablets)
[0055]
[0056] Preparation process: Mosapride citrate is passed through a 120-mesh sieve, and hydroxypropyl cellulose is passed through a 100-mesh sieve. Mosapride citrate, hydroxypropyl cellulose, cross-linked polyvinylpyrrolidone, microcrystalline cellulose, lactose, and micro-powdered silica gel are mixed evenly, and magnesium stearate is added and mixed evenly. A shallow concave punching tablet with a diameter of 7 mm is selected, and the tableting speed and pressure are adjusted to obtain a tablet. The cumulative dissolution amount of the mosapride citrate dispersible tablet is detected.
[0057] Comparative Example 2
[0058] Prescription (1000 tablets)
[0059]
[0060] Preparation process: Mosapride citrate is passed through a 120-mesh sieve, and hydroxypropyl cellulose is passed through a 100-mesh sieve. Mosapride citrate, hydroxypropyl cellulose, cross-linked polyvinylpyrrolidone, microcrystalline cellulose, lactose, and micro-powdered silica gel are mixed evenly, and magnesium stearate is added and mixed evenly. A shallow concave punching tablet with a diameter of 7 mm is selected, and the tableting speed and pressure are adjusted to obtain a tablet. The cumulative dissolution amount of the mosapride citrate dispersible tablet is detected.
[0061] Comparative Example 3
[0062] Prescription (1000 tablets)
[0063]
[0064] Preparation process: Mosapride citrate is passed through a 120-mesh sieve, and hydroxypropyl cellulose is passed through a 100-mesh sieve. Mosapride citrate, hydroxypropyl cellulose, low-substituted hydroxypropyl cellulose, microcrystalline cellulose, lactose, and micro-powdered silica gel are mixed evenly, and magnesium stearate is added and mixed evenly. A shallow concave punching tablet with a diameter of 7 mm is selected, and the tableting speed and pressure are adjusted to obtain a tablet. The cumulative dissolution amount of the mosapride citrate dispersible tablet is detected.
[0065] Comparative Example 4
[0066] Prescription (1000 tablets)
[0067]
[0068] Preparation process: Mosapride citrate is passed through a 120-mesh sieve, and hydroxypropyl cellulose is passed through a 100-mesh sieve. Mosapride citrate, hydroxypropyl cellulose, low-substituted hydroxypropyl cellulose, microcrystalline cellulose, lactose, and micro-powdered silica gel are mixed evenly, and magnesium stearate is added and mixed evenly. A shallow concave punching tablet with a diameter of 7 mm is selected, and the tableting speed and pressure are adjusted to obtain a tablet. The cumulative dissolution amount of the mosapride citrate dispersible tablet is detected.
[0069] Verification Example
[0070] 1. Dissolution
[0071] Weigh 50 mg of mosapride citrate and an appropriate amount of mosapride citrate nanocrystals (containing about 50 mg of mosapride citrate) respectively, and follow the dissolution and release determination method (Method 2, Part 4 General Rules 0931 of the Chinese Pharmacopoeia 2020 Edition), use 900 ml of pH 6.8 phosphate buffer as the dissolution medium, and rotate at 50 revolutions per minute. Operate according to the law. After 30 minutes, take an appropriate amount of solution, centrifuge, take 5 ml of the supernatant, put it in a 100 ml volumetric flask, and dilute it to the scale with the dissolution medium as the test solution; take an appropriate amount of mosapride citrate reference substance, accurately weigh it, add the mobile phase to dissolve it and quantitatively dilute it to make a solution containing about 0.28 mg per 1 ml, accurately measure 1 ml, put it in a 100 ml volumetric flask, dilute it to the scale with the dissolution medium, shake well, and use it as the reference substance solution. The determination was carried out according to the high performance liquid chromatography method (Chinese Pharmacopoeia 2015 Edition Part IV General Rules 0512), using octadecylsilane bonded silica gel as the filler; acetonitrile-methanol-citrate buffer as the mobile phase, the detection wavelength was 274nm, the column temperature was 40°C, 50μl of the test solution and the reference solution were accurately measured and injected into the liquid chromatograph respectively, the chromatogram was recorded, and the dissolution amount was calculated. The results are shown in Table 1.
[0072] Table 1 Dissolution of Mosapride Citrate Nanocrystals
[0073] sample raw material Example 1 Example 2 Example 3 Example 4 Dissolution (%) 46 73 66 84 78
[0074] The results show that the solubility of mosapride citrate nanocrystals is improved compared with the raw material, and Example 3 has the best solubility performance.
[0075] 2. The weight difference, hardness, friability and disintegration time during tableting were investigated. The results are shown in Table 2.
[0076] Table 2 Comparison of tablet quality inspection items between the embodiment and the comparative example
[0077] Example Weight difference (%) Average hardness(N) Friability (%) Disintegration time (min) Example 5 -1.5~2.2 40.43 0.12 1~2 Example 6 -1.7~1.9 38.96 0.09 1~2 Example 7 -2.0~2.0 41.02 0.12 1~2 Example 8 -1.8~2.3 42.75 0.10 1~2 Comparative Example 1 -2.1~1.2 39.67 0.09 <1 Comparative Example 2 -1.4~2.4 37.55 0.11 <1 Comparative Example 3 -2.2~1.6 40.82 0.11 <1 Comparative Example 4 -1.9~1.7 38.29 0.12 <1
[0078] 3. Determination of dissolution curve
[0079] Take mosapride citrate nanochips and follow the dissolution and release determination method (Chinese Pharmacopoeia 2020 Edition, Part IV, General Rules, 0931, Method 2), with pH 1.2 hydrochloric acid solution, pH 4.0 acetate buffer, water, and pH 6.8 phosphate buffer 900ml as the dissolution medium, the speed is 50 revolutions per minute, operate according to the law, take samples in the intermediate process, take 10ml each time (replenish 10ml at the same time), centrifuge, take 5ml of the supernatant, put it in a 10ml volumetric flask, dilute to the scale with the dissolution medium, and use it as the test solution; take an appropriate amount of mosapride citrate reference substance, accurately weigh it, add the mobile phase to dissolve it and quantitatively dilute it to make a solution containing approximately 0.28mg per 1ml, accurately measure 1ml, put it in a 100ml volumetric flask, dilute to the scale with the dissolution medium, shake well, and use it as the reference solution. According to the high performance liquid chromatography method (Chinese Pharmacopoeia 2020 Edition Part IV General Chapter 0512), octadecylsilane bonded silica gel was used as the filler; acetonitrile-methanol-citrate buffer was used as the mobile phase, the detection wavelength was 274nm, the column temperature was 40°C, and 50μl of the test solution and the reference solution were accurately measured and injected into the liquid chromatograph respectively. The chromatogram was recorded and the dissolution amount of each tablet was calculated.
[0080] The dissolution results are shown in Tables 3 to 6.
[0081] Table 3 Solubility in hydrochloric acid solution at pH 1.2
[0082]
[0083]
[0084] Table 4 Dissolution in acetate buffer solution at pH 4.0
[0085]
[0086] Table 5 Dissolution in pH 6.8 phosphate buffer solution
[0087]
[0088] Table 6 Solubility in aqueous solution
[0089]
[0090] From Tables 2 to 6, it can be seen that although the comparative examples have a short disintegration time, their dissolution rates in the four media are all lower than those of the examples. The examples all dissolve about 90% in the four media within 30 minutes, but the comparative examples do not dissolve 80% in the pH 6.8 phosphate buffer solution within 30 minutes.
[0091] In summary, compared with the prior art, the prepared mosapride citrate nanochips of the present invention have fast dissolution speed in different media, high bioavailability, simple preparation process, low production energy consumption, and are suitable for scale-up production.
Claims
1. A mosapride citrate nanocrystalline chip, characterized in that: The formula is composed of the following by mass percentage: Mosapride Citrate Nanocrystals 10% Filler 84% Disintegrant 5% Glidant 0.5% Lubricant 0.5%; The mosapride citrate nanocrystals are prepared from mosapride citrate and a stabilizer by a high-pressure homogenization method. The specific preparation method comprises: preparing a stabilizer ethanol solution, dispersing mosapride citrate in the stabilizer ethanol solution to form a mosapride citrate suspension; placing the mosapride citrate suspension in a high-pressure homogenizer for high-pressure homogenization circulation to obtain a mosapride citrate mixed liquid; spray drying the mixed liquid to obtain mosapride citrate nanocrystals; adding a filler, a disintegrant, a glidant, and a lubricant to the mosapride citrate nanocrystals, mixing them evenly, and then tableting to obtain mosapride citrate nanocrystalline sheets; The filler is one or more of microcrystalline cellulose, pregelatinized starch, mannitol, and lactose; the disintegrant is one or more of cross-linked polyvinylpyrrolidone, low-substituted hydroxypropyl cellulose, cross-linked sodium carboxymethyl cellulose, and sodium starch glycolate; the glidant is one or more of talc and silicon dioxide; and the lubricant is one or more of magnesium stearate and sodium stearyl fumarate; The stabilizer is hypromellose E5; the mass ratio of the stabilizer to mosapride citrate is 1:(0.5-2).
2. The mosapride citrate nanocrystalline wafer according to claim 1, characterized in that: The concentration of mosapride citrate in the mosapride citrate suspension is 10 mg / mL to 30 mg / mL.
3. The mosapride citrate nanocrystalline wafer according to claim 1, characterized in that: The high-pressure homogenization circulation pressure is 600-1000 bar, and the number of cycles is 5-20 times.
4. The mosapride citrate nanocrystalline wafer according to claim 1, characterized in that: The spray drying temperature is 60-70°C.
